Longevity AI partners with Israel’s leading HMO

New digital longevity AI platform emerges from stealth as it seeks to ‘revolutionize how proactive healthcare is delivered.’

Tel Aviv-based digital health company Longevity AI emerged from stealth today, unveiling its platform that allows hospitals, insurance providers, and other medical organizations to track and monitor the health of their patients in real-time. Longevity AI revealed that it has joined forces with KSM, the research and innovation arm of Maccabi Healthcare Services, Israel’s leading health maintenance organization, to “model the aging process and slow it down with tailored medical AI.”

Using anonymized big data resources, the partners will conduct joint research designed to help medical professionals proactively prevent chronic disease – initially focusing on cardiovascular disease, the world’s leading cause of death.

Longevity.Technology: The Longevity AI platform combines evidence-based-medicine and behavioural science designed to enhance healthspan, making risk predictions that support early diagnosis and interventions against major age-related diseases. ‍By using artificial intelligence to make personalized recommendations, the company aims to help medical professionals provide tailored treatment plans designed to improve life expectancy and quality of life. To learn more, we spoke to Longevity AI founder and CEO, Guy Leitersdorf.

While there are many consumer-focused health apps on the market, Longevity AI is squarely focused on the other side of longevity – the medical professionals, insurers and others tasked with maintaining our health. The platform’s main dashboard ‍provides insights that help doctors understand the lifestyle changes that can have the greatest impact on their patients.

Longevity AI interview

“We want to work with health providers, we want to work with doctors to help people understand what are the two or three things that will most help you avoid getting a specific disease,” says Leitersdorf. “Because we believe that if your lifestyle changes are prescribed by a doctor, you’re much more inclined to actually do it.”

Targeting cardiovascular disease

Longevity AI aims to empower clinicians to prescribe effective nutrition, exercise, sleep and mindfulness plans tailored to an individual’s health and preferences.

“We want to be a co-pilot for doctors – giving medical facilities the tools to communicate with their patients because they may be seeing them 10 or 20 years before they even have a condition,” says Leitersdorf.

Longevity AI interview

Of course, focusing on medical professionals means that Longevity AI can only use longevity interventions and approaches that have concrete evidence-based medicine behind them. Leitersdorf uses cardiovascular disease as an example.

“Chronic disease care accounts for 80% of healthcare budgets in Western economies, and the biggest of them all is cardiovascular disease,” he says. “The gold standard for measuring CVD risk is the Framingham Risk Score, which is essentially based on the data of 5,000 Caucasian men in one village in the United States. There have been some advancements over the years, but it is almost the same as it was 70 years ago.”

Empowering clinicians with longevity data

Longevity AI is aiming to build on established standards like Framingham, first to expand them with more diverse and localized data, and then to enhance them with additional insights based on a patient’s medical history, genetics and/or lifestyle.

“When doctors see it, they love it, because first they see the gold standard is already there, so they’re secure,” says Leitersdorf. “But then we can also include things like lifestyle in the risk measurements, because we can identify the ‘needle movers’ – the parameters that are putting you at a high risk. It may be glucose levels, or it can be your steps, or it can be the fact that you’re sleeping too little.”

“We know how to bring mobile and wearable data into the clinical world through our algorithms. So, we’re able to include well-established parameters, like steps, in the formula, and you get significantly increased accuracy.”

This mission to enhance CVD care is what the new partnership with KSM is all about.

“Together, we have the opportunity to revolutionize how proactive healthcare is delivered,” says Leitersdorf. “Empowering Maccabi’s doctors to prescribe healthier lifestyle – tailored to the health status and preference of each member in real-time.”

A personal longevity mission

As the former head of data science at an advertising software firm, Leitersdorf explains that he left the company to focus on longevity after his father was diagnosed with stage 4 cancer.

Longevity AI interview
Guy Leitersdorf, founder and CEO of Longevity AI

“I was really bewildered about my father’s diagnosis – stage 4 cancer is pretty advanced, and he was already under surveillance because he had a heart condition,” he says.

While his father unfortunately passed away, Leitersdorf remained focused on the fact that medical professionals today often aren’t considering the whole picture when it comes to healthcare.

“People who are 50, 60, 70, they often have comorbidities, but the challenge is that today, we only follow specific chronic diseases,” he says. “But it’s not about tackling one disease, it’s about giving people better healthspan.”

Longevity AI interview
The Longevity AI team

Leitersdorf assembled a group of friends and former colleagues to consider building a technology solution designed to help medical professionals give people more healthier years. And so, Longevity AI was born.

“I previously specialized in advertising AI technology, which is basically all about understanding people’s micro behaviours, their trajectory, and how we can impact it for the better,” he says. “At Longevity AI, we’re taking some of these learnings from advertising and applying them to longevity, to see how we can create healthier habits.”